A Study of LY4515100 in Participants With Pain Following Third Molar Removal
- Age
- 18 – 40
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 212 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.
Loading trial locations…
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
CONTACT
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
CONTACT